Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer.

AIM Prognostic value of the cyclin E overexpression in breast cancer has not been clearly established, especially in relation to the pattern of recurrence. We investigated the implication of cyclin E overexpression for the pattern of recurrence in Korean breast cancer patients. METHODS Using immunohistochemical methods, we retrospectively examined the cyclin E expression level in breast cancer specimens from 128 women who underwent curative breast surgery, and correlated the levels of expression with the pattern of relapse in patients. RESULTS Cox model-based multivariate analysis indicated that distant relapse could be predicted by the number of positive axillary lymph nodes, high cyclin E expression, and the younger age (<35 years) of the patient. We tested further the association of cyclin E overexpression with the specific types of recurrence; multivariate analyses indicated that adjusted relative risks of bone and visceral relapse as the first events among high cyclin E group were 2.46 (95% confidence interval (CI), 0.86-7.02) (P=0.092), and 3.98 (95% CI, 1.23-12.94) (P=0.022), respectively. On the other hand, cyclin E overexpression was not associated with the risk of locoregional relapse. CONCLUSION Our data suggest that cyclin E overexpression in primary breast carcinoma tissue could independently predict the risk of distant relapse, especially of visceral relapse, as the first failure after curative breast surgery.

[1]  K. Scott,et al.  Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer. , 1997, British Journal of Cancer.

[2]  I. Schieren,et al.  Effects of cyclin E overexpression on cell growth and response to transforming growth factor beta depend on cell context and p27Kip1 expression. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[3]  Herman Yeger,et al.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.

[4]  James M. Roberts,et al.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.

[5]  D. Bortner,et al.  Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E , 1997, Molecular and cellular biology.

[6]  Stephen J. Elledge,et al.  Cell Cycle Checkpoints: Preventing an Identity Crisis , 1996, Science.

[7]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[8]  G. Landberg,et al.  Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. , 1996, British Journal of Cancer.

[9]  James M. Roberts,et al.  A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.

[10]  R. A. Evans.  The tumor burden of locally recurrent breast cancer is a neglected prognostic factor. , 1996, American journal of surgery.

[11]  T. Hunter,et al.  Dependence of Cyclin E-CDK2 Kinase Activity on Cell Anchorage , 1996, Science.

[12]  L Piana,et al.  Age as a prognostic factor in breast cancer: Relationship to pathologic and biologic features , 1995, International journal of cancer.

[13]  U. Veronesi,et al.  Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Neuberg,et al.  Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Lees,et al.  Cyclin E, a potential prognostic marker for breast cancer. , 1994, Cancer research.

[16]  C. Kamby,et al.  Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. , 1989, British Journal of Cancer.

[17]  H. Mouridsen,et al.  Incidence and methodologic aspects of the occurrence of liver metastases in recurrent breast cancer , 1987, Cancer.

[18]  Y. Nomura,et al.  International comparisons concerning breast cancer and steroid receptors. , 1986, Anticancer research.

[19]  V. Vaitkevicius,et al.  Clinical application of estrogen receptor in breast cancer , 1980, Cancer.

[20]  D. Kern,et al.  Detection of private and common tumor‐associated antigens in murine sarcomas induced by different chemical carcinogens , 1976, International journal of cancer.

[21]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.